SCHEMBL6791259

SCHEMBL6791259

O=S(=O)(c1cccc2ccccc12)C1NCCS1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HTR6 P50406 7/20 0.38
F2 P00734 2/20 0.38
PRSS1 P07477 2/20 0.38
PRSS2 P07478 2/20 0.38
PRSS3 P35030 2/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
AKR1B1 P15121 1/20 0.37
LOXL2 Q9Y4K0 2/20 0.36
MAOA P21397 1/20 0.36
LOX P28300 1/20 0.36
CYP2D6 P10635 1/20 0.36
HCRTR1 O43613 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21358891 0.74 MAPT (0.37) TSHRCA1CA2CA9KMT2A
SCHEMBL8484443 0.71 HTR6 (0.50) CA1CA2CA9HTR6
SCHEMBL20789878 0.71 CA1 (0.55) TSHRCA1CA2CA9MEN1
SCHEMBL6789087 0.71 CA1 (0.44) TSHRCA1CA2CA9MEN1
SCHEMBL6097914 0.68 CA1 (0.52) TSHRCA1CA2CA9MEN1
SCHEMBL3240747 0.67 MEN1 (0.53) TSHRCA1CA2CA9MEN1
SCHEMBL8796437 0.67 KDM1A (0.43) TSHRHTR6HTR2ACYP2D6
SCHEMBL294005 0.67 CA1 (0.46) TSHRCA1CA2CA9MEN1
SCHEMBL334411 0.66 HTR6 (0.45) TSHRCA1CA2CA9MEN1
SCHEMBL3071825 0.65 CA1 (0.68) TSHRCA1CA2CA9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6784184-B2 FOR THERAPY OF RAS- ONCOGENE-DEPENDENT TUMORS, SUCH AS CANCERS OF PANCREAS, COLON, BLADDER, AND THYROID; USEFUL FOR CONTROLLING METASTASIS, SUPPRESSING ANGIOGENESIS, INDUCING APOPTOSIS, AND RAS-ASSOCIATED PROLIFERATIVE DISEASES WYETH HOLDINGS CORPORATION 2004-08-31 US disclosed
US-6605628-B1 Treatment of ras oncogene-dependent tumors; controlling metastasis, suppressing angiogenesis, inducing apoptosis WYETH HOLDINGS CORPORATION 2003-08-12 US disclosed